New metastasectomy criteria for peritoneal metastasis of hepatocellular carcinoma: A study of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery

Abstract

Among extrahepatic metastases of hepatocellular carcinoma (HCC), the incidence rate of peritoneal metastasis (6%-11%) is much lower than the lung, bone, lymph node, or adrenal gland metastasis rates. 1,2 HCC larger than 5 cm, the presence of vascular invasion, a positive resection margin, poorly differentiated HCC, and radiofrequency ablation on HCC near the liver surface are considered to be risk factors for peritoneal metastasis. 3,4 HCC treatment guidelines in Japan recommend systemic chemotherapy, that is, treatment with molecular

Surgical Treatment of Postoperative Abdominal Metastases of Hepatocellular Carcinoma: 10-Year Experience in a Single Center

“…The 5-year OS rate of patients with an abdominal cancer index (PCI) ≤6 and no residual tumor was 43%, and their prognosis was much better than that of patients who did not meet those criteria. 18 In this study, the median survival time of the 15 patients was 18.6 months, and the median DFS time was 6.5 months. Among these patients, 3 had a DFS of more than 5 years.…”

“…The 5-year OS rate of patients with an abdominal cancer index (PCI) ≤6 and no residual tumor was 43%, and their prognosis was much better than that of patients who did not meet those criteria. 18 …”

Development and validation of a nomogram to predict overall survival in patients with incidental gallbladder cancer: A retrospective cohort study

“…Statistically, approximately 7-7.6% of patients with peritoneal metastasis were found to have reoperation ( 23 , 24 ), which was similar to our results (6.3% of patients with peritoneal metastases during reoperation). Evidently, the poor prognosis association with peritoneal metastasis has also been demonstrated in multiple abdominal cancers, such as colorectal, gastric and liver cancers ( 25 – 27 ).…”

Metastasis of Hepatocellular Carcinoma in the Pouch of Douglas Successfully Treated by Radiation Therapy: A Case Report

“…Recently, systemic treatments for HCC have advanced [ 11 , 12 ] and can be used for patients with extrahepatic lesions [ 4 , 5 , 11 , 12 , 13 ]. However, some reports have suggested that the resection of a disseminated tumor may have beneficial effects on the prognosis [ 14 , 15 , 16 ]. Some studies have also suggested the clinical utility of cytoreductive surgery in combination with other therapies [ 17 , 18 ].…”